This blog post and the ensuing discussion present an interesting and revealing dialogue on the practicality of creating an open marketplace for biotech patents; the benefits of open-licensing must be weighed against the high capital and time requirements for vetting and development. Share this page
About the Author
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Network and Share
Also from thinkBiotech
Translator
